The Hill has published an op-ed by Aimed Alliance’s Director of Public Policy, Stacey L. Worthy, entitled “Congress: Keep the nation’s drug safety system intact.” By separating fact from fiction, Ms. Worthy discusses how Risk Evaluation and Mitigation Strategies (REMS) safeguards do not serve as a barrier to generic drug development, nor are REMS used to block generic manufacturers from acquiring samples necessary to create cheaper alternatives. Rather, REMS works to advance patient safety and provide patients access to innovative medicines that otherwise would not see the light of day. Read her full op-ed on the Congress Blog here.
Last Updated on May 8, 2020 by Aimed Alliance
